AU2015237253B2 - Compositions and methods for treating neurodegenerative diseases - Google Patents

Compositions and methods for treating neurodegenerative diseases Download PDF

Info

Publication number
AU2015237253B2
AU2015237253B2 AU2015237253A AU2015237253A AU2015237253B2 AU 2015237253 B2 AU2015237253 B2 AU 2015237253B2 AU 2015237253 A AU2015237253 A AU 2015237253A AU 2015237253 A AU2015237253 A AU 2015237253A AU 2015237253 B2 AU2015237253 B2 AU 2015237253B2
Authority
AU
Australia
Prior art keywords
optionally substituted
alkyl
hydrogen
amide
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015237253A
Other languages
English (en)
Other versions
AU2015237253A1 (en
Inventor
Michael J. Brownstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azevan Pharmaceuticals Inc
Original Assignee
Azevan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azevan Pharmaceuticals Inc filed Critical Azevan Pharmaceuticals Inc
Publication of AU2015237253A1 publication Critical patent/AU2015237253A1/en
Priority to AU2019253831A priority Critical patent/AU2019253831B2/en
Application granted granted Critical
Publication of AU2015237253B2 publication Critical patent/AU2015237253B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2015237253A 2014-03-28 2015-03-27 Compositions and methods for treating neurodegenerative diseases Active AU2015237253B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019253831A AU2019253831B2 (en) 2014-03-28 2019-10-23 Compositions and methods for treating neurodegenerative diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461971862P 2014-03-28 2014-03-28
US61/971,862 2014-03-28
PCT/US2015/023060 WO2015148962A1 (en) 2014-03-28 2015-03-27 Compositions and methods for treating neurodegenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019253831A Division AU2019253831B2 (en) 2014-03-28 2019-10-23 Compositions and methods for treating neurodegenerative diseases

Publications (2)

Publication Number Publication Date
AU2015237253A1 AU2015237253A1 (en) 2016-10-20
AU2015237253B2 true AU2015237253B2 (en) 2019-11-14

Family

ID=54196457

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015237253A Active AU2015237253B2 (en) 2014-03-28 2015-03-27 Compositions and methods for treating neurodegenerative diseases
AU2019253831A Active AU2019253831B2 (en) 2014-03-28 2019-10-23 Compositions and methods for treating neurodegenerative diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019253831A Active AU2019253831B2 (en) 2014-03-28 2019-10-23 Compositions and methods for treating neurodegenerative diseases

Country Status (22)

Country Link
US (4) US9802925B2 (enExample)
EP (1) EP3122743B1 (enExample)
JP (2) JP7255967B2 (enExample)
KR (2) KR20160130853A (enExample)
CN (3) CN116327950A (enExample)
AU (2) AU2015237253B2 (enExample)
BR (1) BR112016022575A2 (enExample)
CA (1) CA2944211C (enExample)
DK (1) DK3122743T3 (enExample)
ES (1) ES2939959T3 (enExample)
FI (1) FI3122743T3 (enExample)
IL (1) IL248074B (enExample)
MX (2) MX382453B (enExample)
MY (1) MY184878A (enExample)
NZ (1) NZ724718A (enExample)
PL (1) PL3122743T3 (enExample)
RU (1) RU2742773C2 (enExample)
SG (2) SG10202001065SA (enExample)
SI (1) SI3122743T1 (enExample)
TW (2) TWI736519B (enExample)
WO (1) WO2015148962A1 (enExample)
ZA (1) ZA201606673B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107007596A (zh) 2010-07-01 2017-08-04 阿泽凡药物公司 用于治疗创伤后应激障碍的方法
NZ724718A (en) 2014-03-28 2023-04-28 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
TWI622380B (zh) * 2017-01-17 2018-05-01 正崴精密工業股份有限公司 生理訊號測量裝置及其血氧濃度演算方法
WO2019055913A1 (en) * 2017-09-15 2019-03-21 Azevan Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY
KR20230124992A (ko) * 2020-12-23 2023-08-28 셀진 코포레이션 신경변성 질환의 치료를 위한 카르복실산 함유 인다닐화합물
WO2023164710A1 (en) * 2022-02-28 2023-08-31 The Trustees Of Columbia University In The City Of New York Avpr1a blockade to reduce social isolation-induced anxiety in females

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558598A1 (en) * 2002-10-25 2005-08-03 Pfizer Limited Triazole compounds for the treatment of dysmenorrhoea

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
NL7503310A (nl) 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
US4576753A (en) 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4341698A (en) 1979-06-21 1982-07-27 Richardson-Merrell Inc. Enkaphalin derivatives
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
JPS6033439B2 (ja) 1980-03-07 1985-08-02 財団法人相模中央化学研究所 ジペプチドの製造方法
JPS56125361A (en) 1980-03-07 1981-10-01 Sagami Chem Res Center Azetidinone compound
FR2508035A1 (fr) 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
US4761501A (en) 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4751299A (en) 1983-11-18 1988-06-14 Takeda Chemical Industries, Ltd. Optically active β-lactams and method of their production
US4665171A (en) 1985-07-17 1987-05-12 Harvard University Process and intermediates for β-lactam antibiotics
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4734498A (en) 1986-07-10 1988-03-29 Eli Lilly And Company 3β-succinimidoazetidinones as chiral intermediates
US4772694A (en) 1986-07-24 1988-09-20 Eli Lilly And Company Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
JP3208139B2 (ja) 1990-10-02 2001-09-10 ワーナー−ランバート・コンパニー アンギオテンシン▲ｉｉ▼アンタゴニスト
GB9204001D0 (en) 1992-02-25 1992-04-08 Jacobs Suchard Ag Process for producing reduced fat nuts
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5612336A (en) 1992-07-13 1997-03-18 Merck, Sharp & Dohme Ltd. Heterocyclic amide derivatives as tachykinin antagonists
DK0655055T3 (da) 1992-08-13 2001-01-02 Warner Lambert Co Tachykininantagonister
FR2696178B1 (fr) 1992-09-30 1994-12-30 Sanofi Elf Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
AU678023B2 (en) 1993-05-06 1997-05-15 Aventis Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5759865A (en) 1995-05-03 1998-06-02 Eli Lilly And Company Combinatorial process for synthesizing azetidinone analogs
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
AU1977997A (en) 1996-02-23 1997-09-10 Eli Lilly And Company Non-peptidyl vasopressin v1a antagonists
EP1000062B1 (en) 1997-07-30 2004-09-22 Wyeth Tricyclic vasopressin agonists
US6403632B1 (en) 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
US6054453A (en) 1997-10-27 2000-04-25 Redd's Research Foundation Tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them
EP2305251A3 (en) 1999-08-16 2011-05-18 Revaax Pharmaceuticals LLC Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of sexual disorder
GB0019006D0 (en) 2000-08-04 2000-09-20 Astrazeneca Ab Novel compounds
MXPA04003358A (es) * 2001-10-12 2004-07-08 Serenix Pharmaceuticals Llc Antagonistas de vasopresina v1a de ?-lactamilo.
WO2003051314A2 (en) 2001-12-18 2003-06-26 Medallion Biomedical, Llc Antibiotic compounds
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
EP2287165A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20060281728A1 (en) 2003-10-03 2006-12-14 Guillon Christophe D 3-Substituted beta-lactamyl vasopressin v1a antagonists
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
EP1669776A1 (de) 2004-12-11 2006-06-14 Leica Geosystems AG Handhaltbares Vermessungsgerät und Vermessungsverfahren für ein solches Vermessungsgerät
FR2881744B1 (fr) 2005-02-09 2007-04-27 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
AU2006227199A1 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
CA2608718A1 (en) 2005-05-18 2006-11-23 Pfizer Limited 1, 2, 4-triazole derivatives as vasopressin antagonists
CA2615813C (en) 2005-07-19 2015-12-15 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
WO2007109615A2 (en) 2006-03-21 2007-09-27 Azevan Pharmaceuticals, Inc. β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS
US20100016274A1 (en) 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
CN101541807A (zh) 2006-09-22 2009-09-23 詹森药业有限公司 用作血管升压素拮抗剂的螺环苯并氮杂
JP5450108B2 (ja) 2007-03-23 2014-03-26 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤としての２−アミノピリジン類似体
US20090182011A1 (en) * 2008-01-16 2009-07-16 University Of Illinois Chicago Chimeric Nitrate Esters and Use of the Same in a Treatment for Depression
FR2927625B1 (fr) 2008-02-19 2010-03-12 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
FR2930249B1 (fr) 2008-04-21 2010-05-14 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
CN107007596A (zh) 2010-07-01 2017-08-04 阿泽凡药物公司 用于治疗创伤后应激障碍的方法
CN105263910A (zh) 2013-02-18 2016-01-20 斯克利普斯研究所 具有治疗潜力的血管加压素受体调节剂
NZ724718A (en) 2014-03-28 2023-04-28 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
WO2019055913A1 (en) 2017-09-15 2019-03-21 Azevan Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558598A1 (en) * 2002-10-25 2005-08-03 Pfizer Limited Triazole compounds for the treatment of dysmenorrhoea

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FABIO K ET AL, "Vasopressin Antagonists as Anxiolytics and Antidepressants: Recent developments", FRONTIERS IN CNS DRUG DISCOVERY 2010 BENTHAM SCIENCE PUBLISHERS B.V. NLD, (2010), vol. 1, ISSN 1879-6613, pages 156 - 183 *
FABIO KARINE ET AL, "Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging", BIOORGANIC & MEDICINAL CHEMISTRY, (2012), vol. 20, no. 3, pages 1337 - 1345 *
Fabio, K., et al, "Vasopressin Antagonists as Anxiolytics and Antidepressants: Recent Developments". Frontiers in CNS Drug Discovery, 2010, vol. 1, pages 156-183 *
FERRIS C F ET AL, "Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, ELSEVIER, US, vol. 83, no. 2, (2006-02-01), pages 169 - 174 *
GUILLON ET AL, "Azetidinones as vasopressin V1a antagonists", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, (2007-01-31), vol. 15, no. 5, doi:10.1016/J.BMC.2006.12.031, ISSN 0968-0896, pages 2054 - 2080 *
N. G. Simon, (2011-11-16), URL: http://www.abstractsonline.com/Plan/AbstractPrintView.aspx?mID=2773&sKey=caca8e2f-554a-4e1c-87b3-13a60b3afc22&cKey=40243821-bb0d-41ab-9945-7bfe090da790, (2017-10-17) *
ROYCE J. LEE ET AL, "A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study", FRONTIERS IN SYSTEMS NEUROSCIENCE, (2013-01-01), vol. 7, doi:10.3389/fnsys.2013.00100 *

Also Published As

Publication number Publication date
CN116139282A (zh) 2023-05-23
FI3122743T3 (fi) 2023-03-02
CA2944211C (en) 2022-10-04
JP7255967B2 (ja) 2023-04-11
US20170174670A1 (en) 2017-06-22
AU2015237253A1 (en) 2016-10-20
AU2019253831B2 (en) 2021-10-28
EP3122743A1 (en) 2017-02-01
TW202216702A (zh) 2022-05-01
JP2017510645A (ja) 2017-04-13
DK3122743T3 (da) 2023-02-20
MX2016012645A (es) 2017-01-11
PL3122743T3 (pl) 2023-05-02
JP2022116001A (ja) 2022-08-09
EP3122743B1 (en) 2022-11-09
NZ724718A (en) 2023-04-28
KR102725123B1 (ko) 2024-11-04
MX382453B (es) 2025-03-13
IL248074B (en) 2020-07-30
RU2016138349A (ru) 2018-05-04
KR20160130853A (ko) 2016-11-14
US11319306B2 (en) 2022-05-03
US20200102294A1 (en) 2020-04-02
SG10202001065SA (en) 2020-04-29
ZA201606673B (en) 2019-06-26
TWI736519B (zh) 2021-08-21
AU2019253831A1 (en) 2019-11-14
CN106459021A (zh) 2017-02-22
RU2016138349A3 (enExample) 2018-10-26
SG11201608064WA (en) 2016-10-28
IL248074A0 (en) 2016-11-30
US20180201608A1 (en) 2018-07-19
CN106459021B (zh) 2023-04-07
MX2021005502A (es) 2023-01-16
TWI839623B (zh) 2024-04-21
TW201620902A (zh) 2016-06-16
BR112016022575A2 (pt) 2017-08-15
US9802925B2 (en) 2017-10-31
CA2944211A1 (en) 2015-10-01
RU2742773C2 (ru) 2021-02-10
EP3122743A4 (en) 2017-11-29
SI3122743T1 (sl) 2023-07-31
US10364236B2 (en) 2019-07-30
ES2939959T3 (es) 2023-04-28
KR20220151037A (ko) 2022-11-11
US20230123729A1 (en) 2023-04-20
MY184878A (en) 2021-04-29
WO2015148962A1 (en) 2015-10-01
CN116327950A (zh) 2023-06-27

Similar Documents

Publication Publication Date Title
US20230123729A1 (en) Compositions and methods for treating neurodegenerative diseases
US10953001B2 (en) Methods for treating post traumatic stress disorder
HK1234030A1 (en) Compositions and methods for treating neurodegenerative diseases
HK1234030B (en) Compositions and methods for treating neurodegenerative diseases
HK1258668B (en) Compounds for use in the treatment of intermittent explosive disorder
HK1184640B (en) Methods for treating post traumatic stress disorder
HK1184640A (en) Methods for treating post traumatic stress disorder
HK1233638B (en) Compositions and methods for treating neurodegenerative diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)